hard to imagine working without it
In the long effort to close the distance between illness and care, the NHS is deploying a coin-sized lens that turns a GP's smartphone into a specialist-grade diagnostic tool. Across England, by July, rural patients and overstretched dermatologists alike may find that geography and waiting lists no longer dictate the pace of a skin cancer diagnosis. It is a small device carrying a large ambition: to catch more cancers earlier, spare thousands of unnecessary journeys, and ask whether technology can quietly absorb some of the weight a strained health system can no longer carry alone.
- With 600,000 skin cancer referrals last year and only 56,000 patients reaching treatment, the gap between suspicion and diagnosis represents a genuine and growing crisis of capacity.
- A 50-pence-sized lens attachable to any smartphone is now the NHS's answer — enabling GPs to photograph lesions in fine enough detail for remote specialist review, collapsing the need for in-person appointments.
- Early trials already diverted roughly 10,000 unnecessary face-to-face consultations, offering particular relief to patients in rural areas where a dermatology clinic can mean an hour's drive each way.
- The ambition is to roughly double the number of patients a single dermatologist can assess in a day, with AI tools running in parallel to test whether algorithms can match a clinician's eye for malignancy.
- The rollout lands against a backdrop of uneven sun-safety habits — one in five British adults still skip sunscreen — underscoring that faster diagnosis alone cannot substitute for the harder work of prevention.
By July, every NHS surgery in England will have access to a device no larger than a 50-pence coin. Clipped to a smartphone, it sharpens an ordinary camera into something precise enough to photograph the fine texture of a mole or suspicious skin patch — clear enough for a specialist to assess from miles away. The NHS calls it teledermatology, and its purpose is both simple and consequential: get skin cancer diagnoses to patients faster.
The need is not abstract. Last year around 600,000 people were referred for skin cancer checks across England, yet only 56,000 received treatment. Dermatologists are stretched, and patients wait. The lens is designed to ease that pressure by allowing GPs — including those in remote rural surgeries — to capture images good enough for remote review, potentially doubling the number of patients a specialist can assess in a single day.
An earlier trial phase revealed an unexpected dividend: roughly 10,000 unnecessary face-to-face appointments were avoided. Patients could be assessed, reassured, or urgently referred without leaving their GP's office. For those in rural communities, where the nearest dermatology clinic might be an hour away, the difference is felt acutely. Somerset GP Dr. Tom While called it transformative — something he could now barely imagine practising without.
NHS chief executive Amanda Pritchard has framed the rollout as essential to managing the system's strain, and the smartphone lens is not arriving alone. The health service is simultaneously trialling an AI tool — Deep Ensemble for the Recognition of Malignancy, or Derm — running its assessments alongside doctors' judgements to test whether the algorithm reaches the same conclusions. Together, these tools signal a broader digital turn in how the NHS intends to absorb demand it can no longer meet through traditional means alone.
The promise is clear: earlier catches, simpler treatments, better outcomes. Whether that promise holds under the full weight of real-world demand is what the coming months will reveal.
By July, every corner of the NHS in England will have access to a device no bigger than a 50-pence coin. Attached to a smartphone, it transforms an ordinary camera into a tool precise enough to photograph the fine detail of a mole or suspicious skin patch—clear enough for a specialist to assess from miles away. The technology, called teledermatology by NHS officials, is meant to do something simple but consequential: get skin cancer diagnoses to patients faster.
Last year, around 600,000 people were referred for skin cancer checks across England. Of those, 56,000 received treatment. The bottleneck is real. Dermatologists are stretched thin, and patients wait. The smartphone lens is designed to ease that pressure by letting general practitioners in remote surgeries capture images good enough for remote review. A specialist doctor reviewing the image can assess far more patients in a single day than they could if each one required an in-person appointment. The hope is to roughly double the number of people a dermatologist can see.
During an earlier trial phase, the system proved its worth in an unexpected way: it prevented about 10,000 unnecessary face-to-face appointments. Some patients who might have made the journey to a clinic could be assessed and reassured—or referred for urgent care—without leaving their GP's office. For people in rural areas, where the nearest dermatology clinic might be an hour's drive, this matters. Dr. Tom While, a GP in Somerset, described it as transformative. "It's a fantastic service and an asset to rural general practice," he said, "and hard to imagine working without it."
The rollout is part of a broader push by NHS leadership to lean on digital tools to manage the system's strain. Amanda Pritchard, the NHS chief executive, framed it as essential: using technology to cut wait times and relieve pressure on an already stretched service. Alongside the smartphone lens, the health service is also testing artificial intelligence systems designed to flag signs of skin cancer. One such tool, called Deep Ensemble for the Recognition of Malignancy (Derm), is being run in parallel with doctors' assessments to see whether the algorithm reaches the same conclusions.
The timing arrives as public health messaging around sun protection remains uneven. A recent poll of 2,000 British adults found that one in five people do not wear sunscreen—a gap that, as charities have noted, often tracks with economic hardship. The faster diagnosis pathway could help catch cancers earlier, when treatment is simpler and outcomes better. What happens next is straightforward: the lens rolls out, GPs begin using it, and the system learns whether the promise of speed and access holds up under the weight of real demand.
Notable Quotes
It's a fantastic service and an asset to rural general practice, and hard to imagine working without it.— Dr. Tom While, GP from Somerset
Championing the use of digital technology is key in reducing wait times and huge pressures on the health service.— Amanda Pritchard, NHS chief executive
The Hearth Conversation Another angle on the story
Why does a device this small matter so much to the NHS right now?
Because 600,000 people a year are waiting to be seen for skin cancer checks, and dermatologists can only see so many in a day. This lens lets a GP take a photo good enough for a specialist to assess remotely. It collapses distance.
But couldn't they just video call a patient?
Not quite the same. A video call is real-time but low resolution. This lens captures the kind of detail a dermatologist needs to spot the difference between a harmless mole and melanoma. It's clinical-grade imaging from a device that costs almost nothing.
The trial avoided 10,000 unnecessary appointments. What does that actually mean?
It means 10,000 people didn't have to travel, didn't have to take time off work, didn't have to sit in a waiting room. Some were reassured they were fine. Others were flagged for urgent care. The system sorted them without the friction.
And the AI piece—is that replacing doctors?
No. It's running alongside them right now, learning. The idea is to flag cases that might need closer attention, not to make the final call. It's a second set of eyes, not a replacement.
What's the risk here?
That the system works in a trial but breaks under real load. Or that rural GPs don't have the training to use it well. Or that the AI makes mistakes no one catches. But the alternative is the status quo—people waiting months for a diagnosis.